UCB S.A.

UCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories.

Contact Details: Allée de la Recherche, 60 Brussels 1070 Belgium Tel: 32/2/559.99.99 Fax: 32/2/559.99.00 Email: contactucb@UCB-Group.com WWW: www.medeva.co.uk/

Recent Publications by UCB S.A.:
Visualization of SV2A conformations in situ by the use of Protein Tomography. The synaptic vesicle protein 2A (SV2A), the brain-binding site of the...	12th August, 2008	Department of Molecular and Cellular Sciences, UCB S.A., Granta Park,	Biochem Biophys Res Commun. 2008 Aug 8. DOI Direct Link
2,6-Quinolinyl derivatives as potent VLA-4 antagonists. A new series of 2,6-quinolinyl derivatives was prepared leading to potent...	25th April, 2007	UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.	Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10. DOI Direct Link
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies. High-throughput screening of the UCB sample collection identified the...	25th April, 2007	CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A.,	Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5. DOI Direct Link
The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro. A protocol for inducing cortical spreading depression (SD) on rat...	3rd February, 2007	UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.	Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11. DOI Direct Link
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. A specific binding site for the antiepileptic drug levetiracetam...	26th July, 2006	UCB S.A., CNS Research, Chemin du Foriest, 1420 Braine L'Alleud, Belgium.	Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10. DOI Direct Link
→View more UCB S.A. research publications.

BioNews Results for UCB S.A.:
DIARY - Western European Corporate events from Oct 01, 2008	Forbes.com:  Oct 1 2008 6:52AM Matching: ucb s
Opioid agonist/antagonist combinations	PharmCast:  Sep 17 2008 8:15PM Matching: ucb s

UCB S.A. Patents:
US Patent No.	Title
6384115	Plasticized polymer compositions
6471970	Use of pharmaceutical compositions capable of being gelled in periodontology
6489329	Pharmaceutical compositions for the treatment of rhinitis
6524804	Process for determining antibiotics containing a .beta.-lactam ring in a biological fluid
6624218	Plasticized polymer compositions
→View more UCB S.A. patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 16 individuals from UCB S.A. using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 183 times since April 2007, the link to the organisation's website has been followed 22 times

Search for more companies in Brussels

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for UCB S.A.